hyperglycaemia

LGD-6972 is an antagonist of glucagon receptor.

BRD3308 is a highly selective inhibitor of HDAC3(IC50 of 54 nM), attenuating PE-mediated phosphorylation of ERK but not JNK.

Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia.

BBO-10203 (Compound 758) is an orally active PI3Kα-Ras interaction disruptor that binds to the RAS-binding domain (RBD) of PI3Kα, disrupting the Ras-PI3Kα interaction and inhibiting Akt activation. It does not significantly affect PI3Kα kinase activity to avoid hyperglycaemia and hyperinsulinaemia, and exhibits activity against KRAS-mutant tumours.

AMPK activator 7 (compound I-3-24) is an AMPK activator with an EC50 of 8.8 nM, useful in studies involving AMPK disorders such as type 2 diabetes, hyperglycaemia, metabolic syndrome, obesity, hypercholesterolaemia, and hypertension.

Ciglitazone (Standard) is the standard substance of Ciglitazone, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia.